# APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline.

- **DOI:** [10.1038/s41586-020-2247-3](https://doi.org/10.1038/s41586-020-2247-3)
- **Rating:** Limited (2.7 out of 5)
- **Verdict:** Multimodal human data link APOE4-related blood-brain barrier injury to cognitive outcomes, but observational associations do not establish the claimed causal pathway.
- **Framework version:** v5.13
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-11-16
- **Evaluation page:** https://www.nabu.science/paper/10.1038%2Fs41586-020-2247-3

## Key claims

1. Our findings suggest that breakdown of the BBB contributes to APOE4-associated cognitive decline independently of Alzheimer's disease pathology, and might be a therapeutic target in APOE4 carriers.
   - Support: Tentative
   - Type: Primary finding
   - Basis: observational associations do not identify a causal contribution independent of AD pathology
   - Location: Abstract; closing summary paragraph
2. High baseline levels of the BBB pericyte injury biomarker soluble PDGFRβ7,8 in the cerebrospinal fluid predicted future cognitive decline in APOE4 carriers but not in non-carriers, even after controlling for amyloid-β and tau status
   - Support: Tentative
   - Type: Secondary
   - Basis: unexamined selection into longitudinal follow-up and uncorrected testing materially limit the predictive evidence
   - Location: Abstract; Results Fig. 3
3. individuals bearing APOE4 (with the ε3/ε4 or ε4/ε4 alleles) are distinguished from those without APOE4 (ε3/ε3) by breakdown of the BBB in the hippocampus and medial temporal lobe
   - Support: Supported
   - Type: Secondary
   - Basis: cross-sectional genotype comparisons support the regional association within a selected imaging subset
   - Location: Abstract; Results Fig. 1b–d
4. The BBB dysfunction (Fig. 1c,d,l,m) preceded brain atrophy (Fig. 1j,k) and was independent of systemic vascular risk factors (Extended Data Fig. 4).
   - Support: Tentative
   - Type: Secondary
   - Basis: cross-sectional cognitive-status comparisons cannot establish within-person temporal ordering
   - Location: Main text, Paragraph 3
5. living APOE4 carriers, but not APOE3 homozygotes, develop an increase in CypA CSF levels with cognitive impairment (Fig. 4h,i), which correlated with elevated CSF sPDGFRβ (Fig. 4j)
   - Support: Supported
   - Type: Secondary
   - Basis: cross-sectional CSF comparisons and correlations support the association without establishing its mechanism
   - Location: Main text, Paragraph 8

## Strengths

- **Human imaging extends prior vascular findings** APOE-stratified BBB imaging combines with fluid biomarkers and cognitive follow-up to extend earlier human BBB observations beyond unstratified associations.
  - Dimension: contribution
  - Location: Introduction, refs 7–8; Results, Figs. 1–3
- **Imaging controls address acquisition and artefacts** MRI acquisition uses standardized protocols and phantom calibration across sites. The tau PET analysis additionally subtracts choroid plexus overlap to address off-target hippocampal signal.
  - Dimension: methodological rigour
  - Location: Methods, Magnetic Resonance Imaging and Analysis; Positron Emission Tomography and Analysis
- **Longitudinal models preserve continuous biomarker information** Mixed models use baseline sPDGFRβ continuously and adjust for amyloid and tau status. The median split is explicitly restricted to visualization rather than statistical testing.
  - Dimension: methodological rigour
  - Location: Fig. 3; Methods, Baseline CSF sPDGFRβ as a Continuous Predictor of Cognitive Decline

## Limitations

- **Causal and chronological conclusions exceed identification** The claim that BBB breakdown contributes to cognitive decline is not established by observational associations. The separate assertion that BBB dysfunction preceded atrophy comes from cross-sectional cognitive-status comparisons rather than longitudinal imaging trajectories.
  - Dimension: methodological rigour
  - Location: Main text, paragraph 3; Abstract and closing summary
- **Subset selection and measurement pooling remain unexamined** DCE-MRI covers 245 of 435 participants, and longitudinal cognition covers 146 of 350 CSF participants without examination of the resulting selection mechanisms. Amyloid PET tracers and different cognitive instruments are also pooled without an assessment of their measurement comparability.
  - Dimension: methodological rigour
  - Location: Methods, Study Participants, PET Analysis and Cognitive Domain Impairment Evaluation; Fig. 3
- **Pathology independence rests on uncertain supporting evidence** Dichotomized CSF adjustment, small PET subsets and uncorrected secondary analyses limit the independence claim. PET totals are reported as 74 amyloid and 96 tau participants, but the overlap breakdown implies 67 and 87, leaving the applicable populations unclear.
  - Dimension: methodological rigour
  - Location: Results, Fig. 2; Methods, Study Participants, PET Analysis and Multiple Comparison Correction

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted. One reported value does not reconcile, but the key claims do not rest on it.
  - BBB breakdown contributes to cognitive decline in APOE4 carriers independent of AD pathology: "Among the 245 DCE-MRI participants, 74 and 96 were additionally studied for brain uptake of amyloid and tau PET radiotracers, respectively" (Methods, Study Participants) vs "This includes those who received both amyloid and tau (n=58), only amyloid (n=9) or only tau (n=29)." (Methods, Positron Emission Tomography and Analysis). The subgroup counts imply amyloid n=58+9=67 and tau n=58+29=87, compared with the stated totals of 74 and 96. → Effect on result unclear
- **Reporting and transparency:** Noted. Ethics approval, informed consent and data availability are declared. Two typographical or labelling slips do not change the reported conclusions.
  - Ethics approval: declared · Data availability: declared
- **Reference integrity:** Noted
  - 58 references in manuscript
  - 55 of 58 checkable references found in an index
  - Could not be verified automatically — queued for manual review:
    - Iturria-Medina Y et al. Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. Nat. Commun 7, 11934 (2016). [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] (Ambiguous: title ratio 0.64 via crossref_bibliographic sits between the divergence (0.30) and match (0.70) thresholds; too close to call either way, so it is recorded as unresolved rather than judged.)
    - Sweeney MD et al. Vascular dysfunction-The disregarded partner of Alzheimer’s disease. Alzheimers Dement. J. Alzheimers Assoc 15, 158–167 (2019). [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] (Ambiguous: title ratio 0.67 via crossref_bibliographic sits between the divergence (0.30) and match (0.70) thresholds; too close to call either way, so it is recorded as unresolved rather than judged.)
    - Cabeen RP, Laidlaw DH & Toga AW Quantitative imaging toolkit: Software for interactive 3D visualization, data exploration, and computational analysis of neuroimaging datasets. in Proceedings of the International Society for Magnetic Resonance in Medicine (ISMRM) vol. 2854 (2018). [ Google Scholar ] (Ambiguous: title ratio 0.54 via crossref_bibliographic sits between the divergence (0.30) and match (0.70) thresholds; too close to call either way, so it is recorded as unresolved rather than judged.)
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-11-16
